Viral hepatitis C
Copyright policy )Viral hepatitis C
More than 170 million people worldwide are chronically infected with the hepatitis C virus (HCV), which is responsible for more than 100000 cases of liver cancer per year, with similar numbers of digestive haemorrhage and ascites episodes. Major breakthroughs have been made in diagnosis and treatment, and advances in molecular biology mean that the replicative state of the virus can now be assessed. Genotype and serum viral load are useful predictors of response to treatment. The combination of pegylated interferon and ribavirin can eradicate the virus in more than 50% of patients. These antiviral treatments reduce liver fibrosis progression and can reverse cirrhosis. Unfortunately, even in developed countries, death due to hepatitis C is increasing because of inadequate detection and treatment.
- Paris 13 University France
- University of Paris France
- University of Hong Kong (香港大學) China (People's Republic of)
- Queen Mary Hospital China (People's Republic of)
- University of Hong Kong China (People's Republic of)
Adult, Liver Cirrhosis, Interferon-alpha - pharmacology - therapeutic use, Genotype, 610, Ribavirin - pharmacology - therapeutic use, Enzyme-Linked Immunosorbent Assay, HIV Infections, Comorbidity, Hepacivirus, Interferon alpha-2, Severity of Illness Index, Antiviral Agents, Hepatitis C, Chronic - diagnosis - drug therapy - epidemiology, Polyethylene Glycols, Viral - analysis - genetics - immunology, Ribavirin, Humans, Hepacivirus - drug effects - genetics - isolation & purification, Serotyping, HIV Infections - drug therapy - epidemiology, RNA, Viral - analysis - genetics - immunology, Polyethylene Glycols - pharmacology - therapeutic use, Interferon-alpha, Hepatitis C, Chronic, Antiviral Agents - pharmacology - therapeutic use, Hepatitis C, Recombinant Proteins, Hepatitis C - diagnosis - drug therapy - epidemiology, Liver Cirrhosis - diagnosis - pathology, Chronic - diagnosis - drug therapy - epidemiology, Interferons - pharmacology - therapeutic use, Disease Progression, RNA, RNA, Viral, Interferons
Adult, Liver Cirrhosis, Interferon-alpha - pharmacology - therapeutic use, Genotype, 610, Ribavirin - pharmacology - therapeutic use, Enzyme-Linked Immunosorbent Assay, HIV Infections, Comorbidity, Hepacivirus, Interferon alpha-2, Severity of Illness Index, Antiviral Agents, Hepatitis C, Chronic - diagnosis - drug therapy - epidemiology, Polyethylene Glycols, Viral - analysis - genetics - immunology, Ribavirin, Humans, Hepacivirus - drug effects - genetics - isolation & purification, Serotyping, HIV Infections - drug therapy - epidemiology, RNA, Viral - analysis - genetics - immunology, Polyethylene Glycols - pharmacology - therapeutic use, Interferon-alpha, Hepatitis C, Chronic, Antiviral Agents - pharmacology - therapeutic use, Hepatitis C, Recombinant Proteins, Hepatitis C - diagnosis - drug therapy - epidemiology, Liver Cirrhosis - diagnosis - pathology, Chronic - diagnosis - drug therapy - epidemiology, Interferons - pharmacology - therapeutic use, Disease Progression, RNA, RNA, Viral, Interferons
selected citations These citations are derived from selected sources.This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).765 popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.Top 1% influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).Top 0.1% impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.Top 0.1%
Citations provided by BIP!Popularity provided by BIP!